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Summary: Human carcinoembryonic antigen (CEA) was measured in perchloric acid extracts from 9 malignant
gastrointestinal tumours, using two different radioimmunological methods (Hoffmann-La Roche and CEA-IRE-
SORIN). When standard curves were set up, quantitative differences in the degree of inhibition were found between
the standards from the two manufacturers. In the Hoffmann-La Roche assay the CEA binding curves of all tumour
extracts ran parallel with the standard. However, when the CEA-IRE-SORIN assay was applied two of the nine
tumours exhibited different slopes. In one case, using the CEA-IRE-SORIN method, various parts of the tumour
exhibited binding curves with non-parallel slopes. The present results suggest that radioimmunologically hetero-
geneous CEA occurs in different gastrointestinal tumours as well as in various parts of the same tumour.
Vergleichende Untersuchungen zur radioimmunologischen Bestimmung von carcinoembryonalem Antigen im Tumor-
gewebe
Zusammenfassung: In Perchlorsäureextrakten aus neun gastrointestinalen Tumoren wurde das carcinoembryonale
Antigen des Menschen (CEA) mit Hilfe zweier radioimmunologischer Methoden (Hoffmann-La Roche und CEA—
IRE—SORIN) bestimmt. Bei der Aufstellung von Standardkurven ergaben sich quantitative Unterschiede zwischen
den Standards der beiden Hersteller in Bezug auf vergleichbare Hemmungen. Bei Verwendung von Hoffmann-La
Roche-Reagenzien verliefen die Bindungskurven für CEA in allen neun Tumorextrakten zum Standard parallel; mit
der CEA—IRE—SORIN-Methode zeigten sich in zwei von neun Fällen unterschiedliche Kurvenverläufe. Bei mehreren
Tumoren wurde CEA in verschiedenen Gewebsanteilen bestimmt. In einem Fall wurden mit der CEA—IRE—SORIN-
Methode an verschiedenen Stellen unterschiedliche Kurvenverläufe beobachtet. Die vorliegenden Befunde sprechen
dafür, daß sowohl in verschiedenen gastrointestinalen Tumoren als auch in verschiedenen Anteilen desselben Tumors
CEA vorkommen kann, welches sich radioimmunologisch heterogen verhält.
Introduction
Human carcinoembryonic antigen (CEA) was first with a tumour extract from a patient, suffering from
described in eolonic carcinomas by Gold &Freedman colonic cancer, Vrba et al. (11) observed differences in
(1). Using radioimmunological methods, CEA has been the binding of the standard and the patient's CEA.
demonstrated in ng-amounts in plasma or serum (2, 3), Furthermore, standard preparations from different
and in extracts from normal and malignant tissues (4, 5). individuals, prepared by identical isolation methods,
Although CEA showed biochemical heterogeneity (6, 7), can lead to different plasma concentrations (13). In
many authors found no qualitative differences between urine qualitative differences between CEA standard and
different standard preparations and extracts from sample have been described, depending on the antiserum
malignant tumours in radioimmunoassays (6, 8, 9). used in the assay (14).
Recently, however, differences have been demonstrated
between various standard preparations with respect to There seem to exist considerable differences between
qualitative and quantitative behaviour in radioimmuno- different CEA standards and antisera; moreover, CEA in
assay (10—13). Comparing a CEA standard preparation plasma and tumour extracts may show radioimmunolog-
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ical heterogeneity, depending on the standard and the
antiserum used. Therefore, in the present study, two
commercially available test kits for the determination of
CEA in extracts from gastrointestinal tumours were
compared. It was found that differences with respect to
the qualitative behaviour of CEA in radioimmunoassay
exist between various tumours and also within the same
tumour.
Materials and Methods
1—6 g tissue from malignant tumours of the gastrointestinal tract
was dissected from normal tissue, frozen and stored at - 20° C
until use. Each specimen was examined histologicaUy to verify
diagnosis. Radioimmunological determinations of CEA were
performed with two commercially available test kits (Hoffmann^
La Roche, Basel, Switzerland, and CEA-IRE-SORIN (CIS1,
distributed by Isotopendienst West, Frankfurt/Main, F. R.
Germany). Tissue was homogenised with an Ultra-Turrax, type
TP-18-10, Janke & Kunkel, Staufen i. Breisgau.
The homogenisation and extraction procedures were performed
at 4°C. The tissue was sliced and homogenised in 4 ml saline
per g tissue; an equal volume of 1.2 mol/1 perchloric acid (15)
was added diopwise to the homogenate during agitation in a
Vortex mixer. The mixture was agitated for 30 min and centri-
fuged at 5000 g for 30 min at 4°C. The supernatant was kept for
further analysis.
For the determination of CEA by the Hoffmann-La Roche
assay, the supernatant was diluted in perchloric acid extracts
from a pool of normal EDTA-plasmas. For this purpose, plasma
from healthy non-smokers with an age of less than 40 years was
diluted 1 : 5 in saline and extracted in 0.6 mol/1 perchloric acid.
Before use the pools were checked for CEA content. The
diluted tumour extracts were dialysed against"repeated changes
of deionized water until the conductance of the water was 1 μ8,
and finally against 0.01 mol/1 ammonium acetate buffer,
pH 6.8. The non-dialy sable residue was tested in the radio-
immunoassay for CEA content. The standard curve was per-
formed with the non-dialysable residue of the dialysed perchloric
acid extract of the normal plasma pool. In order to obtain more
points in the lower concentration range of the standard curve,
the Hoffmann-La Roche standard (CEA^) was diluted in
0.1 mol/1 borate buffer, pH 8.4, containing 10% plasma from
a plasma pool of normal blood donors with the blood group A
Rhpos. This buffer was recieved from Hoffmann-La Roche, Ba-
sel, Switzerland, and is identical with the buffer in which CEA&
is dissolved. The radioimmunoassay was performed according to
the instructions of the manufacturer.
For the determination of CEA by the CIS radioimmunoassay,
the undiluted perchloric acid tumour extracts were dialysed
against deionized water as described above and finally against
0.02 mol/1 veronal buffer, pH 8.3. Double dilutions of the non-
dialysable residue were made in the same buffer. 50 μΐ of the
dilutions were taken for the assay. 50 μΐ of the normal pool
plasma mentioned above were added to the standard tubes and
to the tubes containing the dilutions of the tumour extract.
Addition of antiserum and (12SI]CEA, and the separation of
free and bound antigen were performed according to the in-
structions of the manufacturer.
For the comparison of the standards and for testing the tumour
extracts for maximum inhibition in a combined Hoffmann-La
Roche-CIS-system, the CIS antiserum was dissolved in 0.1· mol/1
borate buffer, obtained from Hoffmann-La Roche. A titration
curve was performed using the Hoffmann-La Roche-assay
system. The titre of the antiserum required to bind 25 % of the
(125I]CEA from Roche was used in the radioimmunoassay.
The response variable
B-N
B0 is the number of counts in the bound fraction without
addition of standard or sample, and Ν is the number of counts in
the precipitate without addition of antiserum. The counting
time was 5 min.
Standards were determined in triplicate and samples in duplicate.
In each separate experiment, the tested extracts were analysed
simultaneously with standards. Standard error of the duplicate
or triplicate determinations was less than ± 5 %.
Results
The binding of the Hoffmann-La Roche standard (CEA)
and of the CEA-IRE-SORIN standard (CEACIS), using
the Hoffmann-La Roehe antiserum (ASR) and the CIS
antiserum (AScis) are demonstrated in figure 1. As can
be seen, the curves run parallel, but a higher amount
of CEAcis was necessary to reach a comparable binding.
To reach 0.50 binding, a 2.5 fold amount of CEACis
was needed as compared to GEAR, when AS^ was
used. A 3.2 fold amount of CEAqs was necessary in
comparison to GEAR, with the antiserum from CIS.
CEA was determined in 9 tumours of the human
gastrointestinal tract by the two different methods.
Using the CIS assay, the binding of CEA in the extracts
from two tumours was clearly different from the
binding of the standard (figs. 2 and 3). In both cases,




was chosen, where Β is the number
of counts in the bound fraction of the sample or the standard,
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Fig. 2. Binding curves of a perchloric acid extract from a colonic
carcinoma and of the CIS standard in the CIS radio-
immunoassay.
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•—· CIS standard
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Fig. 3. Binding curves of perchloric acid extracts from a colonic
and a gastric carcinoma and of the CIS standard in the
CIS radioimmunoassay.
ο—ο colonic carcinoma H.R. (center)
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Fig. 4. Binding curves of a perchloric acid extract from a colonic
carcinoma and of the Hoffmann-La Roche standard in the
Hoffmann-La Roche radioimmunoassay.
ο — ο colonic carcinoma H.R. (center)
• — · Hoffmann-La Roche standard
than the binding curves of CEACis- In the experiment
demonstrated in figure 3, two tumour extracts were
assayed simultaneously. In the case of a gastric carcinoma,
the binding curve runs parallel with the standard curve,
whereas in the case of a colonic carcinoma (H.R.) the
slope of the binding curve is clearly different. In the
Hoffmann-La Roche assay, the binding curve of the
same tumour extract was parallel to the CEAR standard
curve (fig. 4).
The colonic carcinoma H.R. mentioned above was
about 12 cm in diameter, histologically anaplastic and
exhibited a central necrosis. The plasma concentration
in this case, as determined by the Hoffmann-La Roche
assay, was about
With regard to the different behaviour of the perchloric
acid extract of this tumour in comparison with CEAcis
in the CIS assay, tissue specimens were taken from the
central necrotic and from the peripheral tumour parts
and processed separately. The binding curves of the
perchloric acid extracts from the peripheral and central
tissue specimens in the CIS assay are shown in figure 5.
The slope of the extract from the central tissue specimen
is steeper than the slope of the extract from the
peripheral tissue. The same extracts were also analyzed
in the Hoffmann-La Roche assay (fig. 6). No difference
with respect to the slopes of the binding curves could
be demonstrated between the extracts from the central
and peripheral tumour parts.
j. Clin, Chem. Clin. Biochem. / Vol. 16,1978 / No. 6
326 Wagener and Breuer: Comparative studies on the determination of carcinoembryonic antigen
8192
Tissue extract H.R., tumour periphery [dilution]"1









I I I I I I '-
Tissue extract H.R.,tumour center [dilution]"
256 128 64 32 16 8 4
162 4 8
CEA standard [ng]
Fig. 5. Binding curves of perchloric acid extracts from different
parts of a colonic carcinoma and of the CIS standard in the
CIS radioimmunoassay.
ο—ο colonic carcinoma H.R. (center)
ο—α colonic carcinoma H.R. (periphery)
•—· CIS standard
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Fig. 6. Binding curves of perchloric acid extracts from different
parts of a colonic carcinoma and of the Hoffmann^
La Roche standard in the Hoffmann-La Roche radio-
immunoassay.
ο—ο colonic carcinoma H.R. (center)
ο—α colonic carcinoma H.R. (periphery)
•—· Hoffmann-La Roche standard
The tumour extracts were checked for minimum
binding (maximum inhibition) at the lower dilution
ranges with both assays and with a combined assay with
[125I]CEA from Roche and ASos- In i10 case was mini-
mum binding significantly different from the unspecific
binding.
Discussion
In comparison with CEAfc, a higher amount of CEACIS
was needed to reach the same binding of [125I]CEA in
the radipimmuiioassay. This was true for both antisera.
According to the information given by the manufacturer
CEACis was prepared from liver metastases of colonic
carcinomas, using the Gold technique (16). Quantitative
differences between CEAR and standards prepared
according to the Krupey-Gol technique (16) were also
described by Ashman et al. (10) and Vrba et al. (11).
There are several possible explanations for these quan-
titative differences. Persijn &Korsten (14) emphasized
the importance of an exhaustive dialysis of the CEA
preparations in order to exclude salts that would cause
quantitative differences between CEA standard prepa-
rations. A second and third point was stressed by
Newman et al. (17). A variable water content remaining
in the standard preparations after lyophilisation might
also be responsible for quantitative differences. Moreover
varying degree of damage, caused by autolysis, can
markedly lessen the antigenic potency of a preparation
if ion exchange chromatography or gel-block electro-
phoresis are omitted in the isolation procedure. Accord-
ing toEdgington et l. (13) the antigen binding capacity
depends at least in part on the isolation procedure.
We found no qualitative differences between the two
CEA standards. This finding corresponds to the results
of Ashman et al. (10), but is in conflict with Vrba et
al. (11) who described qualitative differences between
CEAR on one hand and three standards from different
sources (GoW/Montreal; Tbdd/Duarte, Calif.; CEA-
British, Med. Res. Council of U.K.) on the other hand.
In contrast to Vrba et al. (11), in the present study the
Hoffmann-La Roche standard curve was measured in a
wider concentration range.
Qualitative differences were found between CEACiS and
two out of nine perchloric acid extracts from gastro-
intestinal tumours, using the CIS radioimmunoassay.
Furthermore, a radioimmunological heterogeneity of
CEA within the same tumour was demonstrated for the
first time. The occurrence of radioimmunologicaUy
different CEA species within the same tumour may be
due either to the synthesis of different CEA species or
to partial degradation of the CEA molecule. The latter
possibility seems more likely, since one of the two tissue
specimens was taken from the necrotic tumour center.
This conclusion is supported by the fact that the CEA
content of the central tumour part was only 1 μg/g
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wet weight, whereas the peripheral part contained
41 §/§ wet weight. The concept that partially degraded
CEA in necrotic tissue may exhibit different binding
curves may explain the findings of Vrba et al. (11) who
described heterogeneity of serum CEA mainly in patients
with very high CEA serum content.
So far, we have studied the radioimmunological behaviour
of CEA in perchloric acid extracts from more than 50
gastrointestinal carcinomas by the Hoffmann-La Roche
assay. None of these tumours showed qualitative radio-
immuriological differences between standard and tumour
CEA.
There are various possible explanations for these find-
ings. The choice of the antiserum plays an important
role in the detection of radioimmunological differences
between different CEA preparations. Our results indicate
that in some antisera there may exist antibody popula-
tions which recognize different antigenic determinants
on distinct CEA species. These antigenic determinants
differ in their affinity for the antibodies. Thus, the dem-
onstration of radioimmunological differences in the
slope of the binding curves depends on the CEA prepara-
tions or the antisera used in the assay. A deficiency of
the antibody population(s) capable of recognizing the
antigenic determinant(s) with different affinities or
a lack of these determinants on the labelled CEA
prevents the demonstration of radioimmunolOgical
differences between the different CEA species.
The standard isolation procedures and the absorption of
the antisera are different in both assays. According to
the information of the manufacturer, CEA-CIS was
prepared by the method ofKrupey et al. (16). A
different isolation procedure was described by Newman
et al. (Hoffmann-La Roche, Nutley, (17)), who stressed
the importance of an additional purification step (ion
exchange) in the isolation procedure in order to exclude
material damaged by autolysis. The CIS antiserum was
raised in rabbits. The immunogen was the same as that
used for the standard and the tracer. The antiserum was
absorbed against extracts from human spleen and lung.
Hansen and co-workers (Hoffmann-La Roche, Nutley,
(18)), described an antiserum, which was induced in
goats against a partially purified perchloric acid extract
from colonic carcinoma (F-l). This antiserum was mono-
specific without further absorption when tested against
perchloric acid extracts from colonic carcinomata and
purified CEA in immunodiffusion.
In both radioimmunoassays and in a combined assay
assay using labelled GEAR and AScis > minimum binding
was reached by all tumour extracts at lower dilution.
Hence, it follows that masking or loss of antigenic deter-
minants in comparison with the CEA standards was not
demonstrable.
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